2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi

 
• By Emily Hayes, Lucie Ellis-Taitt, Lubna Ahmed, Kevin Grogan, Joseph Haas, and Mandy Jackson

PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.

Binoculars
Watching for pharma's Q2 ships to come in • Source: Shutterstock

More from Earnings

More from Business